Aspect Biosystems Ltd. news
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem cells into hepatocytes with the goal of developing biop
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic
Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting 2021, hosted b
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes
Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and Islet Transplant Association Congress 202
Vancouver, BC, Canada, October 4, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mesa to be held October 12-14, 2021 in Carlsbad, CA. This is the third time that the company will be presenting at this conference.
Organized by the Alliance for Reg
Jack Harvey joins the company as Senior Vice President of Process Development & Manufacturing and Rafal P. Witek joins as Head of Therapeutic Cell Platforms
VANCOUVER, British Columbia – September 28, 2021 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce the addition of regenerative medicine and therapeutic development experts to our leadership team: Jack